Page 14 - TD-3-1

Tumor Discovery Haplotype and LD of BRCA genes in GBM

2. Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical diagnostics of hereditary breast and/or ovarian cancer. J Mol
report: Primary brain and other central nervous system Diagn. 2015;17:162-170.
tumors diagnosed in the United States in 2009-2013. Neuro doi: 10.1016/j.jmoldx.2014.11.004
Oncol. 2016;18(suppl_5):v1-v75.
14. Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in
doi: 10.1093/neuonc/now207
the clinic. Science. 2017;355(6330):1152-1158.
3. Kleihues P, Ohgaki H. Phenotype vs genotype in the
evolution of astrocytic brain tumors. Toxicol Pathol. doi: 10.1126/science.aam7344
2000;28(1):164-170. 15. Taza F, Holler A, Fu W, et al. Differential activity of PARP
inhibitors in BRCA1-versus BRCA2-altered metastatic
doi: 10.1177/019262330002800121
castration-resistant prostate cancer. JCO Precis Oncol.
4. Al-Holou WN, Hodges TR, Everson RG, et al. Perilesional 2021;5:1200-1220.
resection of glioblastoma is independently associated with
improved outcomes. Neurosurgery. 2020;86(1):112-121. doi: 10.1200/PO.21.00070
doi: 10.1093/neuros/nyz008 16. Gupta SK, Smith EJ, Mladek AC, et al. PARP inhibitors for
sensitization of alkylation chemotherapy in glioblastoma:
5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy Impact of blood-brain barrier and molecular heterogeneity.
plus concomitant and adjuvant temozolomide for Front Oncol. 2019;8:670.
glioblastoma. N Engl J Med. 2005;352(10):987-996.
doi: 10.3389/fonc.2018.00670
doi: 10.1056/NEJMoa043330
17. Boukerroucha M, Josse C, Segers K, et al. BRCA1 germline
6. Huang B, Yu Z, Liang L. Effect of long-term adjuvant mutation and glioblastoma development: Report of cases.
temozolomide chemotherapy on primary glioblastoma BMC Cancer. 2015;15:181.
patient survival. BMC Neurol. 2021;21:424.
doi: 10.1186/s12885-015-1205-1
doi: 10.1186/s12883-021-02461-9
18. Galisa SLG, Jacob PL, de Farias AA, et al. Haplotypes of
7. Guo C, Yang Q, Xu P, et al. Adjuvant temozolomide single cancer driver genes and their local ancestry in a
chemotherapy with or without interferon alfa among patients highly admixed long-lived population of Northeast Brazil.
with newly diagnosed high-grade gliomas: A randomized Genet Mol Biol. 2022;45(1):e20210172.
clinical trial. JAMA Netw Open. 2023;6(1):e2253285.
doi: 10.1590/1678-4685-GMB-2021-0172
doi: 10.1001/jamanetworkopen.2022.53285
19. Wang S, Qian F, Zheng Y, et al. Genetic variants
8. HGMD. Available from: https://www.hgmd.cf.ac.uk/ac/ demonstrating flip-flop phenomenon and breast cancer risk
introduction.php?lang=english prediction among women of African ancestry. Breast Cancer
9. Kondo N, Takahashi A, Ono K, Ohinishi T. DNA damage Res Treat. 2018;168:703-712.
induced by alkylating agents and repair pathways. J Nucleic doi: 10.1007/s10549-017-4638-1
Acids. 2010;2010:543531.
20. Carrot-Zhang J, Chambwe N, Damrauer JS, et al.
doi: 10.4061/2010/543531 Comprehensive analysis of genetic ancestry and its
10. Quiros S, Roos WP, Kaina B. Rad51 and BRCA2--New molecular correlates in cancer. Cancer Cell. 2020;37:639-
molecular targets for sensitizing glioma cells to alkylating 654.e6.
anticancer drugs. PLoS One. 2011;6:e27183. doi: 10.1016/j.ccell.2020.04.012
doi: 10.1371/journal.pone.0027183 21. Ostrom QT, Egan KM, Nabors LB, et al. Glioma risk
11. Short SC, Giampieri S, Worku M, et al. Rad51 inhibition associated with extent of estimated European genetic
is an effective means of targeting DNA repair in glioma ancestry in African-Americans and Hispanics. Int J Cancer.
models and CD133+ tumor-derived cells. Neuro Oncol. 2020;146:739-748.
2011;13:487-499. doi: 10.1002/ijc.32318
doi: 10.1093/neuonc/nor010 22. Wen PY, Macdonald DR, Reardon DA, et al. Updated
12. Zhang N, Wu X, Yang L, et al. FoxM1 Inhibition response assessment criteria for high-grade gliomas:
sensitizes resistant glioblastoma cells to temozolomide by Response assessment in neuro-oncology working group.
downregulating the expression of DNA-repair gene Rad51. J Clin Oncol. 2010;28(11):1963-1972.
Clin Cancer Res. 2012;18(21):5961-5971. doi: 10.1200/JCO.2009.26.3541
doi: 10.1158/1078-0432.CCR-12-0039
23. Aykan NF, Özatlı T. Objective response rate assessment in
13. Trujillano D, Weiss MER, Schneider J, et al. Next-generation oncology: Current situation and future expectations. World
sequencing of the BRCA1 and BRCA2 genes for the genetic J Clin Oncol. 2020;11(2):53-73.

Volume 3 Issue 1 (2024) 8 https://doi.org/10.36922/td.1480